Xencor (XNCR) Assets (2013 - 2026)
Xencor (XNCR) posted quarterly Assets of $736.8 million for Q1 2026, down 18.55% year-over-year from $904.7 million in Q1 2025, and down 15.84% quarter-over-quarter from $875.5 million in Q4 2025.
Xencor (XNCR) Assets (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Assets for 14 consecutive years, with $736.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 18.55% year-over-year to $736.8 million; the TTM figure through Mar 2026 stood at $736.8 million (down 18.55% YoY), while the FY2025 annual figure was $875.5 million, down 8.03% from the prior year.
- Assets eased to $736.8 million in Q1 2026 per XNCR's latest filing, from $875.5 million in the prior quarter.
- Across five years, Assets topped out at $999.9 million in Q3 2024 and bottomed at $736.8 million in Q1 2026.
- Historically, Assets has averaged $863.0 million across 5 years, with a median of $857.9 million in 2022.
- Annual changes were most pronounced in 2024 — Assets gained 28.45% — and 2026, when it slipped 18.55%.
- Xencor's Assets stood at $846.3 million in 2022, then grew by 14.05% to $965.1 million in 2023, then fell by 1.37% to $951.9 million in 2024, then slipped by 8.03% to $875.5 million in 2025, then dropped by 15.84% to $736.8 million in 2026.
- Business Quant data shows XNCR's Assets at $736.8 million in Q1 2026, $875.5 million in Q4 2025, and $868.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 724.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 724.96 Mn |
| Mar 31, 2026 | 736.85 Mn |
| Dec 31, 2025 | 875.50 Mn |
| Sep 30, 2025 | 868.81 Mn |
| Jun 30, 2025 | 879.42 Mn |
| Mar 31, 2025 | 904.69 Mn |
| Dec 31, 2024 | 951.95 Mn |
| Sep 30, 2024 | 999.90 Mn |
| Jun 30, 2024 | 840.62 Mn |
| Mar 31, 2024 | 896.85 Mn |
| Dec 31, 2023 | 965.14 Mn |
| Sep 30, 2023 | 778.43 Mn |
| Jun 30, 2023 | 778.12 Mn |
| Mar 31, 2023 | 803.41 Mn |
| Dec 31, 2022 | 846.27 Mn |
| Sep 30, 2022 | 835.27 Mn |
| Jun 30, 2022 | 851.33 Mn |
| Mar 31, 2022 | 857.92 Mn |
| Dec 31, 2021 | 838.21 Mn |
| Sep 30, 2021 | 697.26 Mn |